trending Market Intelligence /marketintelligence/en/news-insights/trending/3b0mTLQGeZocHmacotz5xw2 content esgSubNav
In This List

Brasil Pharma Q1 loss narrows YOY

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


Brasil Pharma Q1 loss narrows YOY

Brasil Pharma SA said its normalized net income for the first quarter was a loss of 8.24 reais per share, compared with the S&P Capital IQ consensus estimate of a loss of 12.50 reais per share.

The per-share loss narrowed 65.6% year over year from 23.94 reais.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of 59.8 million reais, compared with a loss of 122.8 million reais in the year-earlier period.

The normalized profit margin increased to negative 7.6% from negative 14.4% in the year-earlier period.

Total revenue declined year over year to 819.3 million reais from 853.1 million reais, and total operating expenses declined 14.4% from the prior-year period to 875.9 million reais from 1.02 billion reais.

Reported net income totaled a loss of 88.6 million reais, or a loss of 12.20 reais per share, compared to a loss of 185.3 million reais, or a loss of 36.14 reais per share, in the year-earlier period.

As of May 13, US$1 was equivalent to 3.01 reais.